Evidence map›Paper›PMID 30291897›Full record

ReviewNanomedicine : nanotechnology, biology, and medicine2019

Protein-based nanoparticles in cancer vaccine development.

Medea Neek, Tae Il Kim, Szu-Wen Wang

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanomedicine : nanotechnology, biology, and medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 2 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 2 syntheses or guidelines pooled it, 162 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Therapeutic vaccines for NSCLC: From mechanisms to clinical translation.Chinese medical journal pulmonary and critical care medicine · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Nanocarriers for cutting-edge cancer immunotherapies.Journal of translational medicine · 2025
    Review
  12. Antibody-Nanoparticle Conjugates in Therapy: Combining the Best of Two Worlds.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Medea NeekDepartment of Chemical and Biomolecular Engineering, University of California, Irvine, CA, USA.
Tae Il KimDepartment of Biomedical Engineering, University of California, Irvine, CA, USA.
Szu-Wen WangDepartment of Chemical and Biomolecular Engineering, University of California, Irvine, CA, USA; Department of Biomedical Engineering, University of California, Irvine, CA, USA; Chao Family Comprehensive Cancer Center, University of California, Irvine, CA, USA. Electronic address: wangsw@uci.edu.
University of California, Irvine · US

Funding

Nanoparticle-Modulated Response Against Tumor-Associated AntigensR21EB017995 · NIBIB · UNIVERSITY OF CALIFORNIA-IRVINE · PI WANG, SZU-WEN · 2014 to 2015
$380k
NIBIB NIH HHS R21 EB017995
6 · The paper itself

Abstract

Peptide and protein-based cancer vaccines usually fail to elicit efficient immune responses against tumors. However, delivery of these peptides and proteins as components within caged protein nanoparticles has shown promising improvements in vaccine efficacy. Advantages of protein nanoparticles over other vaccine platforms include their highly organized structures and symmetry, biodegradability, ability to be specifically functionalized at three different interfaces (inside and outside the protein cage, and between subunits in macromolecular assembly), and ideal size for vaccine delivery. In this review, we discuss different classes of virus-like particles and caged protein nanoparticles that have been used as vehicles to transport and increase the interaction of cancer vaccine components with the immune system. We review the effectiveness of these protein nanoparticles towards inducing and elevating specific immune responses, which are needed to overcome the low immunogenicity of the tumor microenvironment.

Indexed as

Drug Delivery SystemsAdjuvants, ImmunologicAnimalsCancer VaccinesHumansNanoparticlesNeoplasm ProteinsNeoplasmsPeptide FragmentsAdjuvants, ImmunologicCancer VaccinesNeoplasm ProteinsPeptide FragmentsCaged protein nanoparticlesCancer vaccinesTumor antigensVirus-like particles

Identifiers

PMID30291897
PMCPMC6289732
OpenAlexW2895381578

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.